VIC-104959

Synonym(s): LBM-415  |  NVP-PDF-713

Class: Peptide deformylase inhibitor

Spectrum of activity:	Gram-negative
Details of activity:	Growth inhibitor; active against CAP
Institute where first reported:	Vernalis, UK; Novartis, Switzerland; Pfizer, US
Year first mentioned:	2000
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	Toxicity issues (JS) and possible resistance issues

Chemical structure(s):
Canonical SMILES:	CCCC[C@H](CN(C=O)O)C(=O)N1CCC[C@H]1C(=O)N=C2C=CC(=CN2O)F
Isomeric SMILES:	CCCC[C@H](CN(C=O)O)C(=O)N1CCC[C@H]1C(=O)N=C2C=CC(=CN2O)F
InChI:	InChI=1S/C18H25FN4O5/c1-2-3-5-13(10-21(27)12-24)18(26)22-9-4-6-15(22)17(25)20-16-8-7-14(19)11-23(16)28/h7-8,11-13,15,27-28H,2-6,9-10H2,1H3/t13-,15+/m1/s1
InChI Key:	AYCMYBACERJYNY-HIFRSBDPSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9690139

External links:
Guide to Pharmacology:	LBM-415
Citations:	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC152502/ http://www.ncbi.nlm.nih.gov/pubmed/16189089